Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Safety and Efficacy Study of the Svelte Drug-Eluting Coronary Stent Delivery System (DIRECT II)

9 de abril de 2021 atualizado por: Svelte Medical Systems, Inc.

Direct Implantation of Rapamycin-Eluting Stents With Bio-Erodible Drug Carrier Technology Utilizing the Second Generation Svelte Drug-Eluting Coronary Stent Integrated Delivery System (IDS)

A prospective, randomized, active-control, multi-center clinical trial comparing the safety and efficacy of the Svelte Drug-Eluting Coronary Stent Integrated Delivery System (IDS) to that of the commercially available Resolute IntegrityTM Drug-Eluting Stent.

The study objective is to assess the safety and efficacy of the Svelte Drug-Eluting Coronary Stent Integrated Delivery System (IDS) compared to the Resolute IntegrityTM Drug-Eluting Stent in patients with single, never previously treated coronary artery lesions

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Real)

159

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

  • Alemanha
      • Hamburg, Alemanha
        • University Medical Center Hamburg-Eppendorf
      • Hamburg, Alemanha
        • Medizinisches Verzorgungszentrum Prof. Mathey, Prof. Schofer
  • Bélgica
      • Aalst, Bélgica
        • OLV Ziekenhuis Aalst
      • Antwerpen, Bélgica
        • Middelheim Ziekenhuis
      • Genk, Bélgica
        • ZOL Genk
      • Liege, Bélgica
        • CHU Liège
  • França
      • Rouen, França
        • Clinique Saint-Hilaire
      • Toulouse, França
        • CHU de Toulouse
      • Toulouse, França
        • Clinique Pasteur
  • Holanda
      • Amsterdam, Holanda
        • OLVG Amsterdam
      • Eindhoven, Holanda
        • Catharina Hospital Eindhoven
      • Rotterdam, Holanda
        • Maasstad ziekenhuis
      • Rotterdam, Holanda
        • Erasmus MC
      • Utrecht, Holanda
        • University Medical Center Utrecht, Department of Cardiology
  • Suécia
      • Malmo, Suécia
        • Skane University Hospital
      • Stockholm, Suécia
        • Södersjukhuset
  • Suíça
      • Bern, Suíça
        • Inselspital
  • Tcheca
      • Prague, Tcheca
        • Vseobecna fakultni nemocnice Praha

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

General Inclusion Criteria

  1. Patient is ≥18 years old;
  2. Patient is eligible for percutaneous coronary intervention (PCI);
  3. Patient is an acceptable candidate for emergent coronary artery bypass graft (CABG) surgery;
  4. Patient has clinical evidence of ischemic heart disease, stable or unstable angina, silent ischemia, or a positive functional study;
  5. Female subjects of childbearing potential must have a negative pregnancy test within 7-days before the trial procedure;
  6. Patient or subject's legal representative has been informed of the nature of the trial and agrees to its provisions and has provided written informed consent as approved by the Hospital Research Ethics Committee (HREC) of the respective investigational site; and
  7. Patient agrees to comply with specified follow-up evaluations and to return to the same investigational site where the procedure was performed.

Angiographic Inclusion Criteria

  1. Patient has either a single target lesion, or two lesions (target and non-target) located in separate coronary arteries;

  2. If a non-target lesion is treated, it must be treated first and only with commercially available PTCA balloons and/or stents. Post PCI of the non-target vessel, all of the following conditions must be met:

    1. Residual diameter stenosis < 30%;
    2. Absence of any angiographic complications;
    3. Absence of ischemic symptoms; and
    4. Absence of significant new arrhythmia or ECG monitoring changes suggestive of ischemia.
  3. Reference vessel ≥ 2.5 mm and ≤ 3.5 mm in diameter by visual estimate;
  4. Target lesion < 20 mm in length by visual estimate (the intention is to cover the entire lesion with one stent of adequate length); and
  5. Target lesion stenosis ≥ 50% and < 100% by visual estimate.

Exclusion Criteria:

General Exclusion Criteria

  1. Patient is currently enrolled in another investigational device or drug trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials;
  2. The patient requires a staged procedure of the target vessel within 6-months or a staged procedure of a non-target vessel within 30-days post-procedure;
  3. The target lesion requires treatment with a device other than PTCA prior to stent placement (such as, but not limited to, directional coronary atherectomy, excimer laser, rotational atherectomy, etc.);
  4. Any DES deployment anywhere in the target vessel within the past 9-months;
  5. Any BMS deployment anywhere in the target vessel within the past 6-months;
  6. Any previous stent placement within 10 mm (proximal or distal) of the target lesion;

  7. Myocardial infarction within 72-hours of the index procedure, with the exception of:

    1. Patients who have had a STEMI and PCI to the culprit lesion may be included if they have a suitable lesion in another vessel, and have been clinically and hemodynamically stable for 72-hours;
    2. Patients who have had a non-STEMI may be included if their troponin levels are within the laboratory normal range within 24-hours pre-procedure.
  8. Co-morbid condition(s) that could limit the patient's ability to participate in the trial or to comply with follow-up requirements, or impact the scientific integrity of the trial;
  9. Concurrent medical condition with a life expectancy of less than 12-months;
  10. Documented left ventricular ejection fraction (LVEF) ≤ 30%;
  11. Unstable angina pectoris from an extra-cardiac cause (Braunwald Class A I-III);
  12. Known allergies to the following: Acetylsalicylic acid (ASA), Clopidogrel bisulfate, Ticlopidine, Prasugrel, Rapamycin, Zotarolimus, PEAIII AcBz, Heparin/ Bivalirudin, or contrast agent (that cannot be adequately premedicated);
  13. Platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3 or a WBC < 3.000 cells/mm3 or hemoglobin < 100g/l;
  14. Acute or chronic renal dysfunction (serum creatinine > 170μmol/L);
  15. History of a stroke or transient ischemic attack (TIA) within the prior 6-months;
  16. Active peptic ulcer or upper gastrointestinal (GI) bleeding within the prior 6-months;
  17. History of bleeding diathesis or coagulopathy or will refuse blood transfusions; and
  18. Patients requiring ongoing anticoagulation with warfarin or dabigatran.

Angiographic Exclusion Criteria

  1. Total occlusion (TIMI 0 or 1);
  2. Target vessel has angiographic evidence of thrombus
  3. Target vessel is excessively tortuous or has heavy calcification;
  4. Significant (> 50%) stenosis proximal or distal to the target lesion that might require revascularization or impede run off;
  5. Target lesion is located in or supplied by an arterial or venous bypass graft;
  6. Ostial target lesion (within 5.0 mm of vessel origin) or any location within the left main coronary artery;
  7. Target lesion involves a side branch > 2.0 mm in diameter; and
  8. Unprotected Left Main coronary disease (stenosis > 50%).

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Svelte Drug-Eluting Coronary Stent
Coronary Stenting
Dispositivo: Coronary Stenting
Comparador Ativo: Medtronic Resolute Integrity Drug-Eluting Stent
Coronary Stenting
Dispositivo: Coronary Stenting

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Angiographic In-Stent Late Lumen Loss (LL)
Prazo: 6-months post-procedure
Defined as the measurements either within the stented segment or within 5 mm proximal and distal to the stent edges.
6-months post-procedure

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Number of Participants Clinically-driven Target Lesion Revascularization (TLR)
Prazo: 1 year post-procedure
Clinically driven TLR is defined as revascularization performed on a patient who returns with clinical symptoms such as unstable angina, that is, chest pain that increases in frequency, intensity or duration.
1 year post-procedure
Number of Participants Composite of Cardiac Death, MI Attributed to the Target Vessel and Clinically Driven Target Lesion Revascularization
Prazo: 1 year post-procedure
Composite of cardiac death, MI attributed to the target vessel and clinically driven target lesion revascularization
1 year post-procedure
Number of Participants Composite of All-cause Mortality, Any MI and Any Revascularization, Target Vessel Revascularization or Revascularization of Non Target Vessels
Prazo: 1 year post-procedure
Composite of all-cause mortality, any MI and any revascularization, target vessel revascularization or revascularization of non target vessels
1 year post-procedure
Number of Participants Stent Thrombosis
Prazo: 1 year post-procedure
The sudden occlusion of a stented coronary artery due to thrombus formation.
1 year post-procedure
Number of Participants Acute Success Rates
Prazo: From index procedure to hospital discharge, an average of 24 hours
Direct Stenting Success, Lesion Success, Procedure Success and Device Failure
From index procedure to hospital discharge, an average of 24 hours
Number of Participants In-stent and In-segment Angiographic Binary Restenosis Rate
Prazo: 6-months post-procedure
The rate which restenosis occurs
6-months post-procedure
In-stent and In-segment Minimum Lumen Diameter
Prazo: 6-months post-procedure
Smallest diameter in the stent or segment area
6-months post-procedure
In-segment Late Lumen Loss
Prazo: 6-months post-procedure
Late lumen loss is the difference in millimeters between the diameter of a stented segment post-procedure compared with the follow-up angiogram
6-months post-procedure
Neointimal Hyperplasia as Measured by OCT
Prazo: 6-months post procedures
(% lumen volume)
6-months post procedures
Strut Coverage
Prazo: 6-months post procedure
(% of struts malapposed, protruding non-covered, protruding covered, non-protruding covered)
6-months post procedure
Number of Participants Target Vessel Failure
Prazo: 1 year post procedure
Composite endpoint of cardiac death, target vessel MI (Q or Non-Q wave), or clinically- driven target vessel revascularization (TVR) by percutaneous or surgical methods.
1 year post procedure

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Svelte Medical Systems, Inc.

Investigadores

  • Investigador principal: Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese de Cardiologia
  • Investigador principal: Stefan Verheye, MD, PhD, Antwerp Cardiovascular Institute

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Links úteis

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de janeiro de 2013

Conclusão Primária (Real)

1 de maio de 2014

Conclusão do estudo (Real)

31 de maio de 2019

Datas de inscrição no estudo

Enviado pela primeira vez

5 de fevereiro de 2013

Enviado pela primeira vez que atendeu aos critérios de CQ

7 de fevereiro de 2013

Primeira postagem (Estimativa)

11 de fevereiro de 2013

Atualizações de registro de estudo

Última Atualização Postada (Real)

4 de maio de 2021

Última atualização enviada que atendeu aos critérios de controle de qualidade

9 de abril de 2021

Última verificação

1 de abril de 2021

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • IP-12-002

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever